216 related articles for article (PubMed ID: 19752573)
1. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Takahashi H; Tomino Y
Kidney Blood Press Res; 2009; 32(4):239-49. PubMed ID: 19752573
[TBL] [Abstract][Full Text] [Related]
2. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
4. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
Nagasu H; Satoh M; Yorimitsu D; Tomita N; Sasaki T; Kashihara N
Kidney Blood Press Res; 2011; 34(2):87-96. PubMed ID: 21273789
[TBL] [Abstract][Full Text] [Related]
7. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
9. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
11. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
Omote Y; Deguchi K; Kono S; Liu W; Kurata T; Hishikawa N; Yamashita T; Ikeda Y; Abe K
J Neurosci Res; 2014 Oct; 92(10):1330-7. PubMed ID: 24839960
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
Okamura K; Ito M; Tanaka K; Chinushi M; Adachi T; Mitsuma W; Hirono S; Nakazawa M; Kodama M; Aizawa Y
Pharmacology; 2009; 83(6):360-6. PubMed ID: 19440002
[TBL] [Abstract][Full Text] [Related]
14. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
[TBL] [Abstract][Full Text] [Related]
15. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
Mizukawa M; Ohmori K; Obayashi A; Ishihara Y; Yoshida J; Noma T; Yukiiri K; Kosaka H; Kohno M
Hypertens Res; 2009 Jul; 32(7):617-24. PubMed ID: 19461650
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
[TBL] [Abstract][Full Text] [Related]
17. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
18. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
[TBL] [Abstract][Full Text] [Related]
19. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
Fujimoto S; Satoh M; Nagasu H; Horike H; Sasaki T; Kashihara N
Nephrol Dial Transplant; 2009 Dec; 24(12):3651-8. PubMed ID: 19666664
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
